期刊文献+

抗结核药物性肝损临床治疗观察

Clinical Treatment Observation of Anti-tuberculosis Drug-induced Liver Damage
原文传递
导出
摘要 目的探讨抗结核药所致肝功能损害的临床治疗方法。方法将抗结核药物性肝损患者88例随机分为治疗组和对照组各44例:对照组给予门冬氨酸钾镁等治疗;治疗组予以甘草酸二胺加还原型谷胱甘肽治疗。2周后观察两组治疗前后患者的临床症状、体征和肝功能等变化情况。结果治疗组和对照组总有效率分别为95.5%和72.7%,治疗组疗效优于对照组,差异有显著性(P<0.05)。两组治疗前后肝功能明显改善,组间比较,差异有显著性(P<0.01)。治疗后治疗组的肝功能恢复情况明显优于对照组(P<0.05)。结论甘草酸二铵联合还原型谷胱甘肽治疗抗结核药物性肝损疗效确切,安全可靠。 Objective To explore clinical treatment of liver damage caused by anti-tuberculosis drugs.Methods Totally 88 cases of anti-tuberculosis drug-induced liver damage patients were randomly divided into the treatment group of 44 cases and the control group of 44 cases.The control group used potassium magnesium aspartate.The treatment group used diammonium glycyrrhizinate combined with reduced glutathione.To observe the change of clinical symptoms and signs and liver function before and after the treatment after 2 weeks.Results The total effective rates in treatment group and control group were respectively 95.5% and 72.7%,the effect of the treatment group was better than that of the control group,there was a significant difference(P0.05).There was significant changes in the liver function of the two groups before and after the treatment,there was significant difference in the comparison between the two groups(P0.01).Liver function recovery of the treatment group after the treatment was better than the control group(P0.05).Conclusion Diammonium glycyrrhizinate combined with reduced glutathione in the treatment of anti-tuberculosis drug-induced liver damage has exactly curative effect,safe and reliable.
作者 常慧澜
出处 《医药论坛杂志》 2010年第16期78-79,共2页 Journal of Medical Forum
关键词 抗结核药 肝损害 甘草酸二铵 谷胱甘肽 肝功能 Anti-tuberculosis drugs Liver damage Diammonium glycyrrhizinat Glutathione Liver function
  • 相关文献

参考文献5

二级参考文献15

  • 1顾昱,尹宜发,李欣,曹劲松.阿拓莫兰对经肝动脉介入化疗栓塞的原发性肝癌患者肝功能的保护作用[J].临床内科杂志,2005,22(11):777-778. 被引量:6
  • 2Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol,2003,41 : 1226-1232.
  • 3Onnerod LP, Horsfleld N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis, 1996,77:37-42.
  • 4Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology, 1997,26,664-669.
  • 5Danan G, Benichou C, Flahault A. Score of suspected drug-induced acute liver disorders. Presentation of an evaluation sheet. Gastroenterol Clin Biol, 1993,17 ( 5 pt 2 ) : H22-H24.
  • 6Iwasa M ,Zeniya M,Kumagi T,et al. Modified diagnostic criteria of drug-induced liver injury proposed by the intemational consensus meeting, Hepatogastroenteroloty,2005,52:869-874.
  • 7Durand F, Jebrak G, Pessayre D, et al. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf, 1996,15 : 394-405.
  • 8Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-inducted hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. AM J Respir Crit Care Med, 1998,157(6 Pt 1 ):1871-1876.
  • 9Tost JR,Vidal R, Cayla J,et al. Severe hepatotoxicity due to anti- tuberculosis drugs in Spain. Int J Tuberc Lung Dis,2005,9:534- 540.
  • 10WHO's Certified [ DB/OL]. WHO Stop TB Department: Global tuberculosis control: surveillance, planning, financing, WHO report 2007 [ 2007-05-10 ]. http://whqlibdoc. who. int/ publications/2007/9789241563141_eng.pdf.

共引文献288

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部